I spent many years building revenue cycle software, and the most expensive surprises were never the headline rate updates. They were the offsets, the phase-ins and the payment policy changes buried on page 900 of a final rule. The 2027 outpatient rule has all three.
CMS finalized it on November 4, the day after an election that handed both chambers of Congress to the other party. Most of the coverage went to the election. Most of the drama you’re about to face is in the rule.
What changed in the 2027 outpatient rule?
The headline number is a 2.3% payment increase for hospitals that meet outpatient quality reporting requirements: a 3.2% market basket update minus a 0.9 percentage point productivity adjustment. Hospitals that miss the reporting requirements lose 2 percentage points. (Becker's)
The rest of the rule is where the work is:
340B-acquired drugs are paid at average sales price minus 28%.
The recoupment of extra payments from 2018 to 2022 speeds up from a 0.5% to a 2% annual cut on nondrug services.
Site-neutral payment expands to imaging without contrast at off-campus provider-based departments.
637 services come off the inpatient-only list, the second year of a three-year phaseout.
Eight more botulinum toxin injection codes need prior authorization in hospital outpatient departments.
The AHA said the update "does not adequately take into account the financial challenges facing hospitals today."
How does the 340B payment cut work?
CMS surveyed hospital drug acquisition costs from January 1 to April 7, 2026, and found big gaps between what 340B hospitals and other hospitals pay for the same drugs. In some cases, the patient's coinsurance, usually 20% of the Medicare payment, was higher than what the hospital paid for the drug. That's the case CMS makes for the cut: it estimates beneficiaries who get a qualifying drug in an outpatient department will save an average of $900, and Medicare drug spending will fall $4.35 billion in 2027.
By law, the cut has to be budget neutral, so CMS raises payment for nondrug outpatient services by the same amount. That means the money doesn't leave the outpatient system; it moves from hospitals with heavy 340B drug volume to services every hospital bills.
Hospitals see it differently. The AHA called it a "continued assault on the 340B program" and said it "will further stress hospitals' ability to care for their patients." Remember that CMS's last 340B cut, starting in 2018, was ruled unlawful by the Supreme Court. Litigation is possible again. Don't budget on it.
Why does the 340B clawback affect hospitals that don't buy 340B drugs?
This is the part most people will miss. When the earlier 340B cuts were overturned, CMS repaid 340B hospitals and decided to recover the extra nondrug payments every hospital had received during those years, when budget neutrality had pushed nondrug rates up. It's been doing that with a 0.5% annual cut to the nondrug conversion factor.
In 2027, that cut jumps to 2% and continues until CMS recovers $7.8 billion, which it expects to finish in 2031. Hospitals that enrolled in Medicare after January 1, 2018, are exempt. Everyone else takes the 2%, whether or not they participate in 340B.
So a non-340B hospital gets a small lift from this year's budget neutrality adjustment and a 2% cut from the clawback on the same services. The net depends on your service mix. Run it; don't guess.
Which outpatient services just went site-neutral?
CMS will pay the lower physician fee schedule equivalent for imaging without contrast at excepted off-campus provider-based departments, including certain bone density scans, X-rays, ultrasounds, CT scans and MRIs. Rural sole community hospitals are exempt. CMS expects $260 million in savings in 2027 and more than $9 billion over 10 years.
In my RCM 2030 book, I told CFOs to expect site-neutral payments to expand and to model the hit if their margins depend on hospital outpatient rates. Clinic visits went site-neutral in 2019. Drug administration followed in 2026. Imaging is 2027. If your strategy leans on the spread between hospital and office rates, get ready now.
What does the inpatient-only phaseout mean for revenue cycle?
The inpatient-only list tells Medicare which surgeries it will pay for only as inpatient stays. Removing 637 services across 11 clinical families, including digestive, respiratory, urinary and maternity care, means more of those procedures can be done and paid as outpatient cases. CMS is also adding several hundred procedures to the list it covers in ambulatory surgery centers.
For revenue cycle, that's a status and site-of-service question. Expect more patient status decisions to land on your utilization review team, more cases to move to outpatient or ASC rates, and some volume to leave the hospital for surgery centers, including ones you don't own. Update your expected reimbursement tables so underpayment reports don't flag the new outpatient rates as errors.
Does the election change any of this?
Not for January. This is a final rule, and the new Congress isn't sworn in until January 3. Congress could legislate changes later, but the president has promised to veto Democratic bills, and overriding a veto takes two-thirds of both chambers.
There's another thing to consider. Site-neutral payment is one of the few health policy ideas with support in both parties, because it scores as savings. Analysts list it alongside PBM reform and prior authorization as the most likely areas for a bipartisan deal. (Managed Healthcare Executive) If anything, a divided government makes more site-neutral policy more likely, not less. That's my best guess, so take it with a grain of salt.
What should CFOs model before January 1?
340B drug revenue at ASP minus 28%, by drug and by service line. Oncology and infusion will carry most of it.
The budget neutrality lift on your nondrug outpatient services.
The 2% clawback offset on the same services, unless you enrolled after January 1, 2018.
Off-campus imaging volume at physician fee schedule rates, by location.
Inpatient-only removals that touch your surgical volume, and how much of it could move to outpatient or ASC settings.
Expected reimbursement updates in your contract management system, so the new rates don't create false underpayment flags or hide real ones.
Quality reporting status, because missing it costs 2 percentage points on top of everything else.
None of these require a consultant. They require someone who owns the model and updates it when the rule changes, which, as this week showed, it will.
If you want to see where your revenue cycle stands on the data and forecasting side, the RCM AI Readiness Scorecard includes a cash forecasting section and counts only what's live today. Grab it here.
Sources: Becker's: CMS ups hospital outpatient pay 2.3%, cuts 340B rates in 2027 · CMS fact sheet: CY 2027 OPPS final rule · AHA statement on the CY 2027 OPPS final rule · Managed Healthcare Executive: what a Democratic Congress means
